Atrial fibrillation, anticoagulation, and stroke

American Journal of Cardiology

Volumn 77, Issue 3, 1996, Pages 38A-44A

  Morley, Joseph ^b   Marinchak, Roger ^b   Rials, Seth J ^b   Kowey, Peter R ^a  

^a LANKENAU HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; PLACEBO; WARFARIN;

ADULT; AGED; AGING; ANTICOAGULANT THERAPY; BRAIN HEMORRHAGE; CARDIOVERSION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; RISK FACTOR; STROKE; TRANSIENT ISCHEMIC ATTACK;

EID: 0030029631     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)89116-3     Document Type: Conference Paper

References (29)

1. Abbott W, Maloney RD, McCabe CC, Lee CE, Wirthlin LS. Arterial embolism: a 44 year perspective. Am J Surg 1982;143:460-464.
2. Kannel W, Abbott R, Savage D, McNamara P. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med 1982;317: 1018-1022.
3. Cairns JA, Connolly SJ: Nonrheumatic atrial fibrillation: Risk of stroke and role of antithrombotic therapy. Circulation 1991;84:469-481.
4. Pritchett ELC. Management of atrial fibrillation. N Engl J Med 1992;326: 1264-1271.
5. The National Heart, Lung, and Blood Institute Working Group on Atrial Fibrillation. Atrial fibrillation: current understandings and research imperatives. J Am Coll Cardiol 1993,22:1930-1934.
6. Repique LJ, Shah SN, Marais GE. Atrial fibrillation - 1992 management strategies in flux. Chest 1992;101:1095-1103.
7. Ezekowitz MD. Personal communication.
8. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thrombo-embolism in atrial fibrillation: I. Clinical features of patients at risk. Ann Intern Mat 1992;116:1-5.
9. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Ilstrup DM. Lone atrial fibrillation in the elderly. A population-based long term study. (Abstr.) Circulation 1989;80(suppl II):409.
10. Atwood J, Albers G. Anticoagulation and atrial fibrillation. Herz 1993;18: 27-38.
11. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized trials. Arch Intern Med 1994;154:1449-1457.
12. Takahashi N, Seki A, Imataka K, Fujii J. Clinical features of paroxysmal atrial fibrillation: an observation of 94 patients. Jpn Heart J 1981;22:143-149.
13. Petersen P, Godtfredsen J. Embolic complications in paroxysmal atrial fibrillation. Stroke 1986;17:622-626.
14. Petersen P, Pedersen F, Johnson A, Madsen EB, Brun B, Boysen G, Godtfredsen J. Cerebral computer tomography on paroxysmal atrial fibrillation. Acta Neural Scand 1989;79:482-486.
15. Morris JJ Jr, Entman M, North WC, Kong Y, McIntosh H. The changes in cardiac output with reversion of atrial fibrillation to sinus rhythm. Circulation 1965;31:670-678.
16. Resnekov L, McDonald L, Complications in 220 patients with cardiac dysrhythmias treated by phased direct current shock, and indications for electro-conversion. Br Heart J 1967;29:926-936.
17. Bjerkelund CJ, Orning OM. The efficacy of autocoagulation therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol 1969;23:208-216
18. Lown B, Perloth MG, Kaidbey S, Abe T, Harken DE. "Cardioversion" of atrial fibrillation: a report on the treatment of 65 episodes in 50 patients. N Engl J Med 1963;269:325-331.
19. Weinberg DM, Mancini GBJ. Anticoagulation for cardioversion of atrial fibrillation. Am J Cardiol 1989;63:745-746.
20. Petersen P, Godtfredsen J. Embolic complications in paroxysmal atrial fibrillation. Stroke 1986;17:622-626.
21. Rokseth R, Storstein O. Quinidine therapy of chronic auricular fibrillation. Arch Intern Med 1963;111:184-189.
22. Petersen P, Boysen G, Godtfredsen J, Andersen CD, Andersen B, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complication in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989;1:175-178.
23. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators: The effect of low dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990;323:1505-1511
24. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ, Rickles FR, Shabetai R, Deykin D, for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation investigators: warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327: 1406-1412.
25. The Stroke Prevention in Atrial Fibrillation Study Group Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation 1991;84: 527-539.
26. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin verus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-691.
27. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C, for the CAFA Study coinvestigators. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 1991;18:349-355.
28. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after ischaemic attack or monor stroke. Lancet 1993;342:1255-1262.
29. Andrews TC, Peterson DW, Doeppenschmidt D, Foster JS, Lucca MJ, Deering JA, LaVeau PJ. Complications of warfarin therapy monitored by the International Normalized Ratio versus prothrombin time ratio. Clin Cardiol 1995;18:80-82.